Libmyris

Adalimumab, the active ingredient in Libmyris, is a TNF inhibitor presented as a subcutaneous injection for subcutaneous use. It treats several autoimmune inflammatory conditions in adult patients, including rheumatoid arthritis, Crohn's disease and plaque psoriasis, by reducing pathological immune activity.

GNH USA supplies Libmyris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and the product complies with EU regulatory standards.

Libmyris (adalimumab) is indicated for inflammatory autoimmune diseases that involve TNF‑α mediated pathways. - Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage. - Psoriatic arthritis: alleviates joint swelling and skin lesions associated with the disease. - Ankylosing spondylitis: improves spinal mobility and reduces chronic back pain. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Plaque psoriasis: clears skin plaques and decreases scaling and redness.

Adalimumab may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema - Upper respiratory tract infection - Headache - Nausea

Serious or Rare Side Effects: - Serious infections such as tuberculosis or sepsis - Malignancies including lymphoma - New or worsening heart failure

Before initiating Libmyris, several safety considerations should be reviewed. - Screen for latent tuberculosis: perform TB testing and treat if positive. - Monitor for infections: advise patients to report fever, cough or unusual symptoms promptly. - Assess cardiac status: avoid use in patients with moderate to severe heart failure. - Avoid live vaccines: do not administer live attenuated vaccines during treatment. - Caution in demyelinating disorders: discontinue if new neurologic symptoms appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause severe infection. - Concurrent biologic immunosuppressants: increase risk of serious infections. - Antifungal agents (e.g., azoles) used for systemic infections: may augment immunosuppression.

Moderate Interactions (Monitor Closely): - Methotrexate: may enhance immunosuppressive effect, monitor blood counts. - Azathioprine or 6‑mercaptopurine: increased risk of bone marrow suppression. - Cyclosporine: may require dose adjustments and infection surveillance.